TTP registry for patients in Spain and Portugal
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This is a real-world registry that collects information about people diagnosed with thrombotic thrombocytopenic purpura (TTP) in Spain and Portugal. It helps researchers understand TTP patterns and outcomes, and participation is voluntary.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with TTP using international consensus criteria (your doctor can confirm).
- You (or an authorized medical decision-maker) can legally agree to join and sign the consent.
- You were age 0 to 99 at the time your TTP diagnosis was made.
- You are able to attend follow-up visits and complete the study steps the team asks for.
- You agree to participate; no consent means you can’t join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a national registry that collects medical information from people diagnosed with a type of blood-clotting disorder called acquired TTP (aTTP). It may help researchers better understand the disease and how it’s managed, without necessarily changing your treatment.
This study looks back at medical records of people with immune-mediated thrombotic thrombocytopenic purpura (TTP), a rare blood clotting disorder. It aims to better understand the disease and how it is treated.
This trial is looking at the immune system's role in thrombotic thrombocytopenic purpura (TTP), a rare blood disorder. It may help researchers understand the condition better and possibly improve future treatments.
This study collects data from people with immune thrombocytopenia (a condition where the immune system destroys platelets, causing low blood counts). It aims to better understand and track the disease over time.
This study collects information from people with immune-mediated thrombotic thrombocytopenic purpura (iTTP) during an acute episode. It aims to better understand and improve care for this rare blood disorder.
This study is testing a new combination of medicines—immune-suppressing drugs, caplacizumab, and plasma infusions—to treat immune-mediated TTP without standard plasma exchange. It aims to make treatment simpler and potentially safer.
Hear when a new Purpura, Thrombocytopenic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.